Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 10, 2025
– Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 –
– Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 –
Read more at globenewswire.com40.85
-3.44 (-7.77%)
Find more stocks in the Stock Screener
MLYS Latest News and Analysis
4 days ago - By: Chartmill
